Abstract
Cancer immunotherapy using antibodies is now part of the standard of care in treating various solid tumors and hematologic malignancies. The primary targets for these antibodies are large-cell-surface molecules that are expressed preferentially by tumor cells and that may also be expressed by normal cells. One approach to antibody therapy is to employ antibodies that target intracellular antigens that are presented by human leukocyte antigen (HLA) molecules on tumor cell surfaces. These peptide/HLA molecules are the natural targets for T cells. Antibodies that target peptide/HLA are known as T cell receptor mimic (TCRm) antibodies. Several such antibodies have been developed and tested preclinically in solid tumors and hematologic malignancies. In addition to using TCRm antibodies for conventional antibody-mediated tumor cell killing, these antibodies can be conjugated to toxins or engineered into chimeric antigen receptor T cells. Although TCRm antibodies are still in preclinical development, they are a promising tool for cancer immunotherapy.
Original language | English (US) |
---|---|
Title of host publication | Immunotherapy in Translational Cancer Research |
Publisher | Wiley-Blackwell |
Pages | 186-200 |
Number of pages | 15 |
ISBN (Electronic) | 9781118684535 |
ISBN (Print) | 9781118123225 |
DOIs | |
State | Published - Apr 13 2018 |
Keywords
- Antibodies
- Antigens
- Cancer
- Human leukocyte antigen (HLA)
- Immunotherapy
- Major histocompatibility (MHC)
- Peptides
- T cell receptor
- T cell receptor-like
ASJC Scopus subject areas
- General Medicine